Xbrane Biopharma AB (publ) filed its Annual on Mar 31, 2023 for the period ending Dec 31, 2022. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2135 SEK | -1.39% | -39.35% | -97.86% |
Apr. 22 | Transcript : Xbrane Biopharma AB - Special Call | |
Mar. 18 | Xbrane Biopharma AB(OM:XBRANE) dropped from S&P Global BMI Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-97.86% | 29.78M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- XBRANE Stock
- News Xbrane Biopharma AB
- Xbrane Biopharma AB Auditor Raises 'Going Concern' Doubt